Vetoquinol SA
PAR:VETO

Watchlist Manager
Vetoquinol SA Logo
Vetoquinol SA
PAR:VETO
Watchlist
Price: 79.3 EUR 1.28% Market Closed
Market Cap: 938.2m EUR
Have any thoughts about
Vetoquinol SA?
Write Note

Relative Value

The Relative Value of one VETO stock under the Base Case scenario is 103.03 EUR. Compared to the current market price of 79.3 EUR, Vetoquinol SA is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VETO Relative Value
Base Case
103.03 EUR
Undervaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
48
Median 3Y
2.1
Median 5Y
2.1
Industry
2.5
Forward
1.7
vs History
87
vs Industry
22
Median 3Y
21.7
Median 5Y
23.4
Industry
21.9
Forward
18.3
vs History
79
vs Industry
30
Median 3Y
15.8
Median 5Y
13.6
Industry
16.5
vs History
65
vs Industry
22
Median 3Y
18
Median 5Y
18.2
Industry
23.6
vs History
96
vs Industry
36
Median 3Y
2.2
Median 5Y
2.2
Industry
2.1
vs History
96
vs Industry
52
Median 3Y
1.9
Median 5Y
1.9
Industry
2.6
Forward
1.4
vs History
80
vs Industry
58
Median 3Y
3.7
Median 5Y
3.6
Industry
5.2
vs History
77
vs Industry
35
Median 3Y
9.3
Median 5Y
9.4
Industry
13.3
Forward
7.6
vs History
82
vs Industry
31
Median 3Y
13.4
Median 5Y
13.8
Industry
16.6
Forward
10.5
vs History
92
vs Industry
33
Median 3Y
14.6
Median 5Y
12.1
Industry
15.6
vs History
74
vs Industry
24
Median 3Y
15.3
Median 5Y
14.4
Industry
19.1
vs History
87
vs Industry
32
Median 3Y
2.3
Median 5Y
2.3
Industry
1.9

Multiples Across Competitors

VETO Competitors Multiples
Vetoquinol SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Vetoquinol SA
PAR:VETO
938.4m EUR 1.7 19.9 8.2 12.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
FR
Vetoquinol SA
PAR:VETO
Average P/E: 30.9
19.9
12%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top